Misplaced Pages

Anti-neurofascin demyelinating diseases

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: It relies too much on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Anti-neurofascin demyelinating diseases" – news · newspapers · books · scholar · JSTOR (June 2022)

Anti-neurofascin demyelinating diseases (anti-NF diseases) refers to health conditions engendered by auto-antibodies against neurofascins, which can produce both central and peripheral demyelination. Some cases of combined central and peripheral demyelination (CCPD) could be produced by them.

  • Chronic inflammatory demyelinating polyneuropathy: Some cases of CIDP are reported to be produced by auto-antibodies against several neurofascin proteins. These proteins are present in the neurons and four of them have been reported to produce disease: NF186, NF180, NF166 and NF155.
  • Neuromyelitis optica: NF auto antibodies can also appear in NMO cases. These antibodies are more related to the peripheral nervous demyelination, but they were also found in NMO.
  • Multiple sclerosis: Also antibodies against Neurofascins NF-155 can also appear in atypical multiple sclerosis and NF-186 could be involved in subtypes of MS yielding an intersection between both conditions. Around 10% of MS cases are now thought to be anti-NF cases.

Current status

Whether ANFAs are part of a unique and emerging disease entity, disease modifiers, or inconsequential remains to be elucidated with time. Anti-neurofascin antibodies are found in multiple sclerosis, and chronic inflammatory demyelinating polyradiculoneuropathy.

History

The first report about a subgroup of MS patients with anti-NF and contactin 2 auto-antibodies was published in 2011

References

  1. Ciron, Jonathan; Carra-Dallière, Clarisse; Ayrignac, Xavier; Neau, Jean-Philippe; Maubeuge, Nicolas; Labauge, Pierre (3 November 2018). "The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathy". Multiple Sclerosis and Related Disorders. 27: 223–225. doi:10.1016/j.msard.2018.11.002. ISSN 2211-0348. PMID 30414563. S2CID 53292167.
  2. ^ Kira, Jun-ichi; Yamasaki, Ryo; Ogata, Hidenori (2019-11-01). "Anti-neurofascin autoantibody and demyelination". Neurochemistry International. Emerging focus areas in Neuroimmunology. 130: 104360. doi:10.1016/j.neuint.2018.12.011. ISSN 0197-0186. PMID 30582947. S2CID 56595020.
  3. Jia, Kun; Zhang, Xu; Zhang, Lin-Jie; Li, Li-Min; Qi, Yuan; Yi, Ming; Zhang, Chao; Yang, Chun-Sheng; Yang, Li (16 January 2019). "Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders". Journal of the Neurological Sciences. 398: 16–18. doi:10.1016/j.jns.2019.01.024. ISSN 0022-510X. PMID 30665067. S2CID 58636411.
  4. Stich O, Perera S, Berger B, Jarius S, Wildemann B, Baumgartner A, Rauer S (March 2016). "Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis". Journal of the Neurological Sciences. 364: 29–32. doi:10.1016/j.jns.2016.03.004. PMID 27084211. S2CID 29204735.
  5. "Multiple Sclerosis Society Website - Welcome to the MS Society - lini…". archive.ph. 2007-06-21. Retrieved 2022-06-29.
  6. Goncalves, Marcus Vinicius Magno; Fragoso, Yara Dadalti (2019-04-08). "The involvement of anti-neurofascin 155 antibodies in central and peripheral demyelinating diseases". Neuroimmunology and Neuroinflammation. 6: 6. doi:10.20517/2347-8659.2019.08. ISSN 2347-8659. S2CID 146038130.
  7. Kawamura, Nobutoshi; Yamasaki, Ryo; Yonekawa, Tomomi; Matsushita, Takuya; Kusunoki, Susumu; Nagayama, Shigemi; Fukuda, Yasuo; Ogata, Hidenori; Matsuse, Dai; Murai, Hiroyuki; Kira, Jun-ichi (2013-08-20). "Anti-neurofascin antibody in patients with combined central and peripheral demyelination". Neurology. 81 (8): 714–722. doi:10.1212/WNL.0b013e3182a1aa9c. ISSN 0028-3878. PMID 23884033. S2CID 20359260.
  8. Gupta, N.; Shirani, A.; Arcot Jayagopal, L.; Piccione, E.; Hartman, E.; Zabad, R. K. (2022). "Anti-Neurofascin Antibodies Associated with White Matter Diseases of the Central Nervous System: A Red Flag or a Red Herring?". Brain Sciences. 12 (9): 1124. doi:10.3390/brainsci12091124. PMC 9497231. PMID 36138860.
  9. Kira, Jun-ichi (January 22, 2021). "Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism". Frontiers in Neurology. 12. doi:10.3389/fneur.2021.665136. PMC 8222570. PMID 34177770.
  10. Kira, Jun-ichi; Yamasaki, Ryo; Ogata, Hidenori (November 1, 2019). "Anti-neurofascin autoantibody and demyelination". Neurochemistry International. 130: 104360. doi:10.1016/j.neuint.2018.12.011. PMID 30582947.
  11. Meinl, Edgar; Derfuss, Tobias; Krumbholz, Markus; Pröbstel, Anne-Katrin; Hohlfeld, Reinhard (6 September 2010). "Humoral autoimmunity in multiple sclerosis". Journal of the Neurological Sciences. 306 (1–2): 180–182. doi:10.1016/j.jns.2010.08.009. ISSN 0022-510X. PMID 20817206. S2CID 22349060.


Stub icon

This neuroscience article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Anti-neurofascin demyelinating diseases Add topic